Johnson & Johnson’s Imaavy (isatuximab-irfc) secured a U.S. label expansion for warm autoimmune hemolytic anemia (wAIHA), making it the first FDA-approved therapy specifically for that rare indication. J&J framed the update as a continuation of the drug’s growing portfolio, after last year’s approval for generalized myasthenia gravis. Imaavy is an antibody therapy designed to target CD38 on immune cells, a mechanism intended to reduce autoantibody-driven red blood cell destruction in wAIHA. The label update gives clinicians an additional option in a disease area where treatment choices have historically been limited. The change also adds momentum for commercial planning across multiple autoimmune and neuromuscular indications. With wAIHA moving into the FDA-cleared lineup, payers and providers are expected to reassess treatment pathways. For biotech teams, the move underscores continued interest in immunology assets with label expansion potential beyond initial launches.